Lenalidomide as induction therapy before allogeneic stem cell transplantation in a patient with proliferative CMML-2 and del(5q) not involving the EGR1 locus.
Platzbecker, U
Lenalidomide as induction therapy before allogeneic stem cell transplantation in a patient with proliferative CMML-2 and del(5q) not involving the EGR1 locus. [electronic resource] - Leukemia Nov 2007 - 2384-5 p. digital
Publication Type: Letter
0887-6924
10.1038/sj.leu.2404811 doi
Aged
Antineoplastic Agents--therapeutic use
Cell Proliferation
Chromosomes, Human, Pair 5
Cytogenetics
Early Growth Response Protein 1--genetics
Gene Deletion
Humans
Lenalidomide
Leukemia, Myelogenous, Chronic, BCR-ABL Positive--genetics
Male
Remission Induction
Stem Cell Transplantation--methods
Thalidomide--analogs & derivatives
Time Factors
Transplantation, Homologous--methods
Lenalidomide as induction therapy before allogeneic stem cell transplantation in a patient with proliferative CMML-2 and del(5q) not involving the EGR1 locus. [electronic resource] - Leukemia Nov 2007 - 2384-5 p. digital
Publication Type: Letter
0887-6924
10.1038/sj.leu.2404811 doi
Aged
Antineoplastic Agents--therapeutic use
Cell Proliferation
Chromosomes, Human, Pair 5
Cytogenetics
Early Growth Response Protein 1--genetics
Gene Deletion
Humans
Lenalidomide
Leukemia, Myelogenous, Chronic, BCR-ABL Positive--genetics
Male
Remission Induction
Stem Cell Transplantation--methods
Thalidomide--analogs & derivatives
Time Factors
Transplantation, Homologous--methods